Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

EB-001

Alternative Names: eb-001, eb001, eb 001
Latest Update: 2023-12-01
Latest Update Note: PubMed Publication

Product Description

Botulinum Neurotoxin Serotype EÊfor participants undergoing abdominoplasty. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03429556)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bonti
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Musculoskeletal Pain|Injuries/wounds Unspecified|Glabellar Reflex

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EB001-SR201

P2

Completed

Injuries/wounds Unspecified

2018-07-31

EB001-ABD201

P2

Terminated

Musculoskeletal Pain

2018-07-10

Breast Augmentation

P2

Completed

Musculoskeletal Pain

2018-04-26

EB001-GL201

P2

Completed

Glabellar Reflex

2017-07-12

Recent News Events

Date

Type

Title

12/01/2023

PubMed

 Botulinum toxin type E associated with reduced itch and pain during wound healing and acute scar formation following excision and linear repair on the forehead: A randomized controlled trial.

03/08/2022

PubMed

 Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions